舒督通痹丸治疗强直性脊柱炎的临床研究

Clinical research on treating ankylosing spondylitis with Shudu Tongbi wan

目的:观察舒督通痹丸治疗强直性脊柱炎的临床疗效。方法:选择有临床症状的强直性脊柱炎病人97例,随机分为治疗组和对照组,治疗组51例服用舒督通痹丸,对照组46例采用缓解病情的西药。疗程6个月,治疗前后评价Bath强脊功能指数(BASFI)、强脊疾病活动指数(BASDAI)、指地距、扩胸度、枕壁距、Schober试验、血沉、C-反应蛋白及血尿便常规、肝肾功能。结果:治疗后两组BASFI、BASDAI、C-反应蛋白均有显著性改善,治疗组BASFI改善优于对照组,治疗组治疗前后血沉、指地距变化有统计学意义(P<0.05),两组Schober试验、枕壁距、扩胸度均无统计学意义(P>0.05)。治疗组总有效率为79.6%,对照组为75.3%(P>0.05)。治疗组中医证候改善优于对照组。结论:舒督通痹丸治疗强直性脊柱炎疗效良好。

Objective： To observe clinical effects of treating ankylosing spondylitis with Shudu Tongbi wan. Methods： Randomly divided 97 cases with ankylosing spondylitis patients into treatment group and control group, in which, 51 patients in treatment group applying Shudu Tongbi wan, while 46 cases in control group applying Western medicine to relieve disease. As 6 months for a course, and evaluate BASFI score, BASDAI score, refers to land distance, thoracic expansion degrees, pillow-wall distance, schober test, ESR, C-reactive protein, the regular text of blood and urine, the text of liver and kidney function before and after the treatment. Results： After the treatment, BASFI score, BASDAI score, ESR and C-reactive protein in two groups showed significant improvement, and BASFI score improvement in treatment group was better than control group; It had statistically significant that ESR and refers to land distance before and after the treatment in treatment group （P〈0.05）, but which had no statistically significant that schober test, pillow-wall distance and thoracic expansion degrees （P〉0.05）. The total effective rate in treatment group was 79.6%, while the control group was 75.3% （P〉0.05）, which improvement of TCM syndrome in treatment group was better than control group. Conclusion： Shudu Tongbi wan bad a better effect in treating ankylosing spondylitis.